Caris Life Sciences, INC Form 4 insider transactions

Caris Life Sciences President David Spetzler reported a disposition of 63,509 common shares at $29.75 for tax obligations under a pre-arranged plan.

Caris Life Sciences CEO David D. Halbert reported a disposition of 141,956 shares of common stock to cover tax liabilities at a price of $29.75 per share.

Caris Life Sciences President David Baxley Spetzler reported multiple changes in his beneficial ownership, including the surrender of shares for debt repayment, acquisition of restricted stock units, and exercise of stock options, all reflecting a recent one-for-four reverse stock split.

Caris Life Sciences, Inc. Chief Financial Officer Luke Thomas Power was awarded 99,321 restricted stock units, increasing his beneficial ownership to 99,571 shares.

A recent SEC Form 4 filing reveals Caris Life Sciences Director Jon Halbert's acquisition of restricted stock units and the conversion of preferred stock into common shares following the company's initial public offering and a one-for-four reverse stock split.

J.H. Whitney VI L.P., a 10% owner and director of Caris Life Sciences, Inc., converted over 50 million shares of Series A Preferred Stock into 12.5 million shares of Common Stock following the company's initial public offering.

John Russel Denton, Senior Vice President, General Counsel, and Secretary of Caris Life Sciences, Inc., reported multiple transactions including stock dispositions for debt repayment, restricted stock unit awards, and stock option grants, alongside a reverse stock split.

David D. Halbert, Founder, Chairman, and CEO of Caris Life Sciences, Inc., reported substantial acquisitions of common stock and conversion of preferred shares following the company's initial public offering and a reverse stock split.

ADAPT I Ltd. and Carisome I, L.P., significant shareholders and directors of Caris Life Sciences, Inc., converted 14 million shares of Series A Preferred Stock into 3,500,003 shares of Common Stock on June 20, 2025, coinciding with the company's initial public offering.

Caris Life Sciences Director Peter M. Castleman has reported changes in his beneficial ownership, including the conversion of preferred stock into common stock and the award of restricted stock units, following a one-for-four reverse stock split and the company's initial public offering.

Brian J. Brille, Vice Chairman and Executive Vice President of Caris Life Sciences, reported acquiring 162,428 shares of common stock through a restricted stock unit award and a direct purchase.

TSSP Sub-Fund HoldCo LLC and Alan Waxman reported the conversion of preferred stock and warrants into over 24 million common shares of Caris Life Sciences, Inc. in connection with the company's initial public offering.